08:17 AM EDT, 09/10/2025 (MT Newswires) -- Camp4 Therapeutics ( CAMP ) said Wednesday that it has signed agreements with certain investors to raise as much as $100 million through a private placement.

The clinical-stage company said the net proceeds from the placement will be used to fund the preclinical and clinical development of its program to treat Syngap1-related disorders, which are rare genetic conditions caused by a variant on the Syngap1 gene.

Camp4 said it will receive $50 million in upfront funding, with the option for an additional $50 million if the company meets certain pre-specified milestones, including regulatory clearance to begin a phase 1/2 trial in Syngap patients with its CMP-SYNGAP-01 candidate.

The company said Coastlands Capital is leading the financing, with participation from Janus Henderson Investors (JHG), Balyasny Asset Management, and others.

Additionally, Camp4 said it has appointed Doug Williams as the chair of its board. The company also said it has promoted Daniel Tardiff, its head of discovery, to chief scientific officer.

Shares of the company were up 70% in recent Wednesday premarket activity.